Weight Loss Peptides
This hub connects approved weight-management medicines with investigational metabolic research. It also includes orforglipron, a non-peptide oral GLP-1 medicine, because readers compare it with peptide-based options.
Category Overview
GLP-1 medicines affect appetite, calorie intake and glucose-dependent insulin secretion. Some investigational compounds also target GIP, glucagon or amylin pathways. A common receptor family does not make formulations, trial outcomes or safety profiles interchangeable.
Compare results by study population, formulation, dose, duration and analysis method rather than treating cross-trial percentages as a league table. For study-specific findings, see our Peptides for Weight Loss guide.
Current product context: Foundayo prescribing information identifies orforglipron as an oral GLP-1 medicine for adult weight management. The FDA AOD-9604 assessment distinguishes the larger negative oral obesity trial from earlier signals and does not establish routine subcutaneous efficacy. Related profiles retain the specific trial sources and evidence-access limits.
Medicines and Research Compounds
Dual GIP/GLP-1 agonist in Mounjaro and Zepbound. These are distinct prescription products with indication-specific labels; obesity-trial averages are not an individual prediction.
GLP-1 agonist in Ozempic, Wegovy and Rybelsus. Product formulation, indication and dose matter; a cardiovascular or weight-management result is attached to its studied population.
Investigational GIP/GLP-1/glucagon triple agonist with encouraging phase 3 weight-loss results. Trial population, dose, duration and estimand determine how those results should be interpreted.
Modified growth-hormone fragment, Tyr-hGH177–191. The larger 502-person oral obesity trial did not establish its primary weight-loss benefit; this does not validate routine injectable treatment.
GLP-1 receptor agonist used in the daily injectable weight-management product Saxenda. Its trial results and label differ from newer products.
Investigational GLP-1/glucagon dual agonist. Obesity and liver-disease trials study different populations and endpoints; read each result in its own context.
Non-peptide small-molecule GLP-1 agonist in Foundayo, an approved once-daily tablet for adult weight management. It belongs in this topic comparison but is not itself a peptide.
Investigational combination of semaglutide and the amylin analog cagrilintide. Cross-trial percentages do not establish superiority to another product.
Key Comparisons
Related Guides
Product distinction: Approved prescription medicines, investigational compounds and research-vendor products have different evidence and access conditions. A research product is not interchangeable with an approved medicine.
Peptide Dossier Editorial Team · Editorial source reconciliation October 27, 2026. Current Foundayo prescribing information and relevant FDA AOD-9604 assessment sections were checked; other entries reuse the linked profiles and their stated source limits. This is an editorial hub check; no clinician review was performed. Methods · Disclosures · Corrections · Explore metabolic research.